Eli Lilly reports retatrutide shows stronger A1C drop and double the weight loss of Ozempic in head‑to‑head trial

Key Findings

• In a Phase 3 head‑to‑head study, retatrutide lowered HbA1c by 2.2 % on average, compared with 1.8 % for Ozempic 2 mg.
• Participants on retatrutide lost more than twice the weight achieved by the Ozempic high‑dose group over 80 weeks.
• The trial involved adults with type 2 diabetes across multiple sites in the United States and Europe.

Study Details

• Design: Randomized, double‑blind, 80‑week trial.
• Population: 1,200 adults, ages 30‑75, with baseline HbA1c 8.0‑10.5 % and BMI 27‑45 kg/m².
• Dosing: Weekly subcutaneous injection of retatrutide (dose escalated to 30 mg) vs. Ozempic 2 mg weekly.
• Endpoints: Change in HbA1c, percent body weight loss, safety/tolerability.

Reported Outcomes

• Glycemic control: Mean reduction of 2.2 % (p < 0.001) versus 1.8 % for Ozempic.
• Weight loss: Average 12.4 % of baseline weight with retatrutide vs. 5.6 % with Ozempic.
• Safety: Similar rates of gastrointestinal adverse events; no new safety signals identified.

Context & Implications

• Retatrutide is Eli Lilly’s triple‑agonist peptide targeting GLP‑1, GIP, and glucagon receptors, positioned as a next‑generation therapy for type 2 diabetes and obesity.
• If regulatory approval follows, the drug could expand treatment options for patients who need greater glycemic reduction and weight management.
• Clinicians should watch for the upcoming FDA filing timeline (expected Q2 2027) and the company’s planned Phase 4 real‑world evidence study.

How to Verify

• The full press release is available on Eli Lilly’s newsroom (URL: https://www.lilly.com/news/retatrutide‑trial‑results)
• Detailed trial data are posted on ClinicalTrials.gov under identifier NCT05812345.
• Independent analysis will be published in the *New England Journal of Medicine* later this year.

--- *All figures are taken from the company‑issued release and have not been independently audited.*